Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS)
Pharmacy · 24.04.2026 · 14 (3) · 63
DOI: 10.3390/pharmacy14030063 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacy, online erschienen am 24.04.2026. Verfasst von Mar Llamas-Velasco und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Universitario de la Princesa, Instituto de Investigación Biomédica de la Princesa, Universidad Autónoma de Madrid…. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Tildrakizumab, an anti-IL-23p19 monoclonal antibody, has demonstrated efficacy in clinical trials, but real-world evidence remains crucial for confirming its profile in diverse populations.
Methods
We have conducted a multicenter, retrospective observational study within the Spanish Psoriasis Group (GPS). This study updates previous findings with a larger sample size (n = 372) and longer follow-up. We assessed absolute Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and the Dermatology Life Quality Index (DLQI) improvements, as well as safety, in patients with moderate-to-severe plaque psoriasis.
Results
The cohort included a large population of patients with a high prevalence of comorbidities and prior biologic exposure. Effectiveness was high, with a significant proportion of patients achieving PASI < 1. Compared to recent real-world data, our cohort demonstrates superior complete clearance rates (PASI < 1) and includes a comprehensive DLQI assessment. Notably, 79 patients were aged ≥65 years, confirming the drug’s utility in the elderly. Safety was consistent with previous reports, with no new signals detected.
Conclusions
Tildrakizumab shows robust effectiveness and safety in a complex, bio-experienced real-world population. The lack of clinical predictors of response suggests a need for future pharmacogenetic exploration.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Hospital Universitario de la Princesa, Instituto de Investigación Biomédica de la Princesa, Universidad Autónoma de Madrid, 28006 Madrid, Spain.
- Department of Dermatology, Hospital Universitario Puerta de Hierro, 28222 Majadahonda, Spain.
- Department of Dermatology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain.
- Department of Dermatology, Hospital Universitario La Paz, 28046 Madrid, Spain.
- Department of Dermatology, Hospital Universitario San Cecilio, Instituto Biosanitario de Granada (IBS.GRANADA), 18016 Granada, Spain.
- Department of Dermatology, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain.
ORCID-Profile: Mar Llamas-Velasco, Mercedes Hospital, Ricardo Ruíz-Villaverde, Raquel Rivera, Salvador Arias, Isabel Belinchon, Javier Mataix, Pablo de la Cueva
Zitieren
APA
Llamas-Velasco, M., Hospital, M., López-Ferrer, A., Herranz, P., Ruíz-Villaverde, R., Mateu, A., García-Latasa, F. J., Rivera, R., Fernández-Freire, L. R., Alcazar, E. D., Santos, S., Arias, S., Gónzalez-Cantero, A., Belinchon, I., Carretero, G., Ferran, M., Ruiz-Genao, D., Eiris, N., Sahuquillo, A., …, & Salgado-Boquete, L. (2026). Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS). Pharmacy, 14(3), 63. https://doi.org/10.3390/pharmacy14030063
Vancouver
Llamas-Velasco M, Hospital M, López-Ferrer A, Herranz P, Ruíz-Villaverde R, Mateu A, et al. Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS). Pharmacy. 2026;14(3):63. doi:10.3390/pharmacy14030063
BibTeX
@article{LlamasVelasco2026,
author = {Llamas-Velasco, Mar and Hospital, Mercedes and López-Ferrer, Anna and Herranz, Pedro and Ruíz-Villaverde, Ricardo and Mateu, Almudena and García-Latasa, Francisco Javier and Rivera, Raquel and Fernández-Freire, Lourdes Rodriguez and Alcazar, Elena Del and Santos, Sergio and Arias, Salvador and Gónzalez-Cantero, Alvaro and Belinchon, Isabel and Carretero, Gregorio and Ferran, Marta and Ruiz-Genao, Diana and Eiris, Noemí and Sahuquillo, Antonio and Mataix, Javier and Carrascosa, Jose-María and Cueva, Pablo de la and Salgado-Boquete, Laura},
title = {Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS)},
journal = {Pharmacy},
year = {2026},
volume = {14},
number = {3},
pages = {63},
doi = {10.3390/pharmacy14030063}
}
EUVIMED